NDA 214154 · Mayne Pharma
Nextstellis
Drospirenone, Estetrol · Oral
NovelCDER novel approval, Apr 15, 2021: To prevent pregnancy
Last checked: Nov 20, 2026Latest source record: Apr 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Apr 15, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
146
48 Phase 3, 7 recruiting
FAERS reports
296
102 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in females over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NEXTSTELLIS, are contraindicated in females who are over 35 years of age and smoke. [See Contraindications (4) and Warnings and Precautions (5.1) ] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning . Females over 35 years old who smoke should not use NEXTSTELLIS ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )
What it is approved for
From the label in effect May 11, 2023.
NEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy. NEXTSTELLIS is a combination of drospirenone, a progestin, and estetrol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use NEXTSTELLIS may be less effective in females with a BMI ≥ 30 kg/m 2 . In females with BMI ≥ 30 kg/m 2 , decreasing effectiveness may be associated with increasing BMI ( 14 ). Limitations of Use NEXTSTELLIS may be less effective in females with a BMI ≥ 30 kg/m 2 . In females with BMI ≥ 30 kg/m 2 , decreasing effectiveness may be associated with increasing BMI [see Clinical Studies (14) ].
Mechanism: CHCs prevent pregnancy primarily by suppressing ovulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 15, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
1 products under this application
- NEXTSTELLIS · DROSPIRENONE 3MG; ESTETROL 14.2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00413062 · 2,281 participants · Start Jun 2006 · Primary completion Aug 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00511199 · 2,152 participants · Start May 1, 2006 · Primary completion Apr 1, 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada StudyPivotal-lookingCompleted
EstetraIndustry
NCT02817841 · 2,148 participants · Start Aug 30, 2016 · Primary completion Oct 16, 2018
Drug: 15 mg E4/3 mg DRSP · For: Contraception
Sites: Philadelphia, Pennsylvania; Québec, Canada
- YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in ChinaCompleted
BayerBayer (BAYRY)
NCT02710708 · 1,921 participants · Start May 27, 2016 · Primary completion Jul 3, 2018
Drug: EE20/DRSP (YAZ, BAY86-5300) · For: Contraception
Sites: Xiamen, China; Guangzhou, China; Shenzhen, China · 38 sites in all
- Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00567164 · 1,887 participants · Start Oct 2007 · Primary completion Nov 2009
Drug: EE20/DRSP (BAY86-5300); EE20/DRSP (BAY86-5300) and 1 more · For: Contraception; Ovulation Inhibition; Contraceptives, Oral
Sites: Montgomery, Alabama; Chandler, Arizona; Mesa, Arizona · 85 sites in all
- E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia StudyPivotal-lookingCompleted
EstetraIndustry
NCT02817828 · 1,577 participants · Start Jun 2016 · Primary completion Apr 26, 2018
Drug: 15 mg E4/3 mg DRSP · For: Contraception
Sites: Brussels, Belgium
- Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 CyclesPivotal-lookingCompleted
Laboratories Leon Farma, S.A.Industry
NCT02269241 · 1,552 participants · Start Oct 9, 2014 · Primary completion Oct 4, 2017
Drug: LF111 (drospirenone) · For: Contraception
Sites: Birmingham, Alabama; Anaheim, California; Costa Mesa, California · 37 sites in all
- Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in FemalesPivotal-lookingCompleted
Insud PharmaIndustry
NCT05461573 · 1,542 participants · Start Aug 2, 2022 · Primary completion Aug 5, 2024
Drug: Drospirenone · For: Contraception; Change in Bone Mineral Density
Sites: Alabaster, Alabama; Birmingham, Alabama; Tucson, Arizona · 47 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- intermenstrual bleeding26
- heavy menstrual bleeding21
- headache16
- drug ineffective15
- dizziness13
- mood swings12
- off label use12
- nausea11
- product use in unapproved indication11
- migraine10
- suicidal ideation10
- weight increased10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 7 |
| 2022 | 75 |
| 2023 | 64 |
| 2024 | 28 |
| 2025 | 45 |
| 2026 | 77 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nextstellis (Drospirenone/Estetrol)
2024 spending
$94K
Beneficiaries
81
267 claims
Per beneficiary
$1,159
$7.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $6,196 |
| 2022 | $36,668 |
| 2023 | $78,373 |
| 2024 | $93,910 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Hormonal contraception in women with endometriosis: a systematic review.
Grandi G, Barra F, Ferrero S, et al. · Eur J Contracept Reprod Health Care 2019 · Systematic Review
- Comparative effectiveness and safety of different progestins in combined oral contraceptives: a systematic review and network meta-analysis of randomized controlled trials.
Li B, Xu X, Xu K, et al. · Arch Gynecol Obstet 2025 · Comparative Study, Network Meta-Analysis
- Estetrol/Drospirenone safety in a population with cardiovascular risk factors.
Creinin MD, Foidart JM, Gemzell-Danielsson K, et al. · Contraception 2025 · Clinical Trial, Phase III
- Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
Pkhaladze L, Russo M, Unfer V, et al. · Eur Rev Med Pharmacol Sci 2021 · Comparative Study, Randomized Controlled Trial
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, et al. · Int J Gynaecol Obstet 2018 · Meta-Analysis, Systematic Review
Sponsor: Mayne Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.